Medicare’s GLP-1 Pricing Initiative: What BALANCE Could Mean for Drug Costs and Coverage
By Naga Vivekanandan Esq. – Medicare has spent years watching GLP-1 drugs move from a promising diabetes therapy to one of the most consequential drivers of prescription drug spending. That shift has been fueled by strong clinical results, expanding indications, and unprecedented demand.
